✦ LIBER ✦

Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa

✍ Scribed by Dr William H. Timberlake; Michael A. Vance

Publisher: John Wiley and Sons
Year: 1978
Tongue: English
Weight: 795 KB
Volume: 3
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.410030206

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Levodopa “drug holiday” with amantadine

Levodopa “drug holiday” with amantadine infusions as a treatment of complications in Parkinson's disease

✍ Dariusz Koziorowski; Andrzej Friedman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The loss of beneficial effect of levodopa due to progression of the disease and alteration of receptor sensitivity makes the treatment of the advanced stadium of Parkinson's disease (PD) very difficult. In the past “drug holidays” was used in attempt to resensitize dopamine receptors in

Ten-year follow-up of Parkinson's diseas

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

✍ Robert A. Hauser; Olivier Rascol; Amos D. Korczyn; A. Jon Stoessl; Ray L. Watts; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

## Abstract In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) mot

Oral solution of levodopa ethylester for

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

✍ Ruth Djaldetti; Rivkah Inzelberg; Nir Giladi; Amos D. Korczyn; Yehudit Peretz-Ah 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double‐blind, levodopa‐controlled, multicenter study of oral

Long-term mortality results of the rando

Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease

✍ Jean-Louis Montastruc; Karine Desboeuf; Maryse Lapeyre-Mestre; Jean-Michel Senar 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB

## Abstract The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocrip

Prognostic impact of hemoglobin levels o

Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone

✍ Daniel T. T. Chua; Jonathan S. T. Sham; Damon T. K. Choy 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

## Abstract ## BACKGROUND The goal of the current study was to investigate the impact of hemoglobin (Hb) levels on treatment outcome in a randomized Phase III trial of patients with nasopharyngeal carcinoma (NPC) treated with induction chemotherapy followed by radiotherapy or with radiotherapy alo

Sumanirole versus placebo or ropinirole

Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease

✍ Paolo Barone; Janice Lamb; Amanda Ellis; Zoe Clarke 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

## Abstract The aims of this study were to assess the safety, tolerability, and efficacy of sumanirole, a highly selective D~2~ dopamine receptor agonist, versus placebo in subjects with advanced Parkinson's disease (PD), and to demonstrate noninferiority of sumanirole to ropinirole. In this flexib